Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 212.34 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 111.89K shares, a 51.40% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 100.45K shares, a 71.20% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 7.55K shares, a 98.62% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 483.60K shares, a 249.42% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.07M shares, a 25.88% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.44M shares, a 359.35% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 314.32K shares, a 1157.78% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 24.99K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 111.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 212.34K shares 10-Q · filed 2026-08-11 | 219.89K shares derived: sum of 3 quarters · filed 2026-08-11 | 703.49K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 100.45K shares 10-Q · filed 2026-05-12 | 108.00K shares derived: sum of 2 quarters · filed 2026-05-12 | 591.60K shares derived: sum of 3 quarters · filed 2026-05-12 | 821.83K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 7.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 491.15K shares derived: sum of 2 quarters · filed 2026-03-03 | 721.38K shares derived: sum of 3 quarters · filed 2026-03-03 | 1.07M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 483.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 713.83K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.06M shares 10-Q · filed 2025-11-06 | 1.61M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 230.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 578.98K shares 10-Q · filed 2025-08-06 | 1.13M shares derived: sum of 3 quarters · filed 2025-08-06 | 1.27M shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 348.75K shares 10-Q · filed 2025-05-12 | 897.01K shares derived: sum of 2 quarters · filed 2025-05-12 | 1.04M shares derived: sum of 3 quarters · filed 2025-05-12 | 1.45M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 548.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 686.66K shares derived: sum of 2 quarters · filed 2025-03-19 | 1.10M shares derived: sum of 3 quarters · filed 2025-03-19 | 1.44M shares 10-K · filed 2025-03-19 |
| 2024-09-30 | 138.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 551.21K shares derived: sum of 2 quarters · filed 2024-11-13 | 895.55K shares 10-Q · filed 2024-11-13 | 1.11M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 412.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 757.15K shares 10-Q · filed 2024-08-12 | 973.25K shares derived: sum of 3 quarters · filed 2024-08-12 | 973.25K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 344.34K shares 10-Q · filed 2024-05-14 | 560.44K shares derived: sum of 2 quarters · filed 2024-05-14 | 560.44K shares derived: sum of 3 quarters · filed 2024-05-14 | 604.37K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 216.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 216.10K shares derived: sum of 2 quarters · filed 2024-03-28 | 260.03K shares derived: sum of 3 quarters · filed 2024-03-28 | 314.32K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 43.92K shares derived: sum of 2 quarters · filed 2023-11-09 | 98.22K shares 10-Q · filed 2023-11-09 | 101.16K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 43.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 98.22K shares 10-Q · filed 2023-08-09 | 101.16K shares derived: sum of 3 quarters · filed 2023-08-09 | |
| 2023-03-31 | 54.29K shares 10-Q · filed 2023-05-05 | 57.24K shares derived: sum of 2 quarters · filed 2023-05-05 | ||
| 2022-12-31 | 2.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 24.99K shares 10-K · filed 2023-03-16 | ||
| 2022-09-30 | 22.04K shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |